Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Novo Nordisk has reached a defining moment in the evolution of the obesity drug market with the U.S. Food and Drug Administration’s approval of a once-daily oral version of Wegovy.</li><li>Announced on December 23, 2025, the decision marks the first FDA-approved oral GLP-1 therapy specifically indicated for chronic weight management, extending Novo Nordisk’s semaglutide franchise beyond injections.</li><li>The approval arrives at a time when growth in injectable Wegovy has begun to moderate in the U.S., payer scrutiny remains elevated, and competition from :contentReference[oaicite:0]{index=0} is intensifying ahead of its own oral GLP-1 candidate, orforglipron.</li></ul>

Novo Nordisk has reached a defining moment in the evolution of the obesity drug market with the U.S. Food and Drug Administration’s approval of a once-daily oral version of Wegovy.Announced on December 23, 2025, the decision marks the first FDA-approved oral GLP-1 therapy specifically indicated for chronic weight management, extending Novo Nordisk’s semaglutide franchise beyond injections.The approval arrives at a time when growth in injectable Wegovy has begun to moderate in the U.S., payer scrutiny remains elevated, and competition from :contentReference[oaicite:0]{index=0} is intensifying ahead of its own oral GLP-1 candidate, orforglipron.

Novo Nordisk’s Wegovy Pill Is Approved—Is This the End for Injections?